Table 3. Multivariable analysis with EFS and OS for the CN-AML patients.
| Variable | OS, n=157 | EFS, n=157 | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| MAPKBP1 expression, high vs low | 1.87 (1.20-2.91) | 0.006 | 1.87 (1.23-2.84) | 0.003 |
| Age, per 10-y increase | 1.17 (1.00-1.35) | 0.036 | 1.08 (0.95-1.24) | 0.251 |
| Sex, male vs female | 0.82 (0.54-1.24) | 0.35 | 0.99 (0.67-1.46) | 0.962 |
| NPM1, mutated vs wild type | 0.5 (0.31-0.79) | 0.003 | 0.52 (0.34-0.81) | 0.004 |
| FLT3-ITD, mutated vs wild type | 1.77 (1.10-2.85) | 0.018 | 1.63 (1.04-2.55) | 0.033 |
| CEBPA, mutated vs wild type | 0.64 (0.34-1.22) | 0.174 | 0.71 (0.39-1.28) | 0.258 |
CN-AML indicates cytogenetically normal acute myeloid leukemia; RFS, relapse-free survival; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence interval; and ITD, internal tandem duplication;